儿科心力衰竭中的empagliflozin:基于模型的药理学桥梁研究的优化
Sebastiano A G Lava1,2,3,4, Alessandro Di Deo2, Salvatore D'Agate2
1Pediatric Cardiology Unit, Department of Pediatrics, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
Frontiers in medicine
|March 11, 2026
概括
这项研究优化了使用empagliflozin的儿科心力衰竭试验的设计. 基于模型的方法成功地推断出成人数据,为儿童建立安全有效的剂量方案.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床试验设计 临床试验设计
- 儿童心脏病学 儿童心脏病学
背景情况:
- 儿童心力衰竭治疗方法有限,许多试验都失败了.
- 将成年药物的疗效推广到儿童是具有挑战性的,但必要的.
研究的目的:
- 优化研究设计,为儿科心力衰竭中对empagliflozin进行前性试验.
- 根据成年人的数据,建立对儿童使用empagliflozin的剂量推理.
主要方法:
- 使用非线性混合效应建模来推断成人的药理动力学数据到儿童.
- 使用优化算法和模拟重新估计程序来改进研究设计元素.
- 虚拟儿科队列被用来克服小人群中的精度问题.
主要成果:
- 确定了一种两部分的药理动力学模型,用于清除和分布的基于体重的全米缩放.
- 使用10毫克的empagliflozin片,确定了15公斤的最低体重作为纳入标准.
- 为12名患者开发了一个优化的采样方案,使得暴露特征和数据收集成为可能.
结论:
- 10毫克的empagliflozin重量带治疗方案适用于儿童患者≥15公斤.
- 基于模型的方法对于优化儿科临床试验设计,最大限度地获取信息和最大限度地减少患者负担至关重要.
更多相关视频
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Metabolism
306
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
306
Pharmacokinetics in Pediatric Patients: Drug Excretion
346
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
346
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
605
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
605
Pharmacokinetics in Pediatric Patients: Drug Distribution
411
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
411
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
59
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
302
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
302


